Spyre Therapeutics (SYRE) investor relations material

Executive summary

• Advanced a pipeline of long-acting monoclonal antibodies for IBD and rheumatic diseases, with multiple Phase 2 trials ongoing and positive topline data for SPY001 in ulcerative colitis and IBD announced in April 2026.

• Achieved a $30.0 million milestone gain from the sale of pegzilarginase rights following regulatory approval in the U.S.

• Raised $435.3 million net ($463 million gross) from an April 2026 public offering, strengthening liquidity and resulting in $1.2 billion pro forma cash as of March 31, 2026.

• Over-enrollment and accelerated topline readout for the RA sub-study of the Phase 2 SKYWAY basket trial, now expected in Q3 2026.

• Six proof-of-concept readouts anticipated in 2026 across SKYLINE and SKYWAY Phase 2 trials.

Financial highlights

• Net loss of $69.0 million for Q1 2026, up from $44.8 million in Q1 2025, driven by increased R&D and G&A expenses.

• Research and development expenses rose 45% year-over-year to $60.4 million, primarily due to higher clinical trial, manufacturing costs, and headcount.

• General and administrative expenses increased 28% to $15.2 million, mainly from higher compensation and headcount.

• Cash, cash equivalents, and marketable securities totaled $741.5 million as of March 31, 2026; pro forma cash of $1,176.8 million including April 2026 offering.

• Net cash used in operating activities was $57.4 million for Q1 2026.

Outlook and guidance

• Sufficient resources to fund operations for at least one year; cash runway expected into the second half of 2029, with additional financing needed for future R&D and commercialization.

• Multiple Phase 2 and proof-of-concept data readouts expected in 2026 and 2027 for IBD and rheumatic disease programs.

• Anticipated topline data for SPY002 and SPY003 in mid and Q3 2026, RA sub-study data in Q3 2026, PsA and axSpA sub-studies in Q4 2026.